Drug Profile
Research programme: 212 Pb immunoconjugates - Orano Med
Alternative Names: alpha radioimmunotherapies - Orano Med; cancer radioimmunotherapies - Orano MedLatest Information Update: 22 Feb 2018
Price :
$50
*
At a glance
- Originator AREVA Med
- Developer INSERM; National Cancer Institute (USA); Orano Med; University of Cincinnati
- Class Drug conjugates; Immunotoxins; Lead radioisotopes; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in France (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for research development in Prostate-cancer in USA (Parenteral)